Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ELUT - ELUTIA INC.

IEX Last Trade
4.12
-0.080   -1.942%

Share volume: 16
Last Updated: Thu 26 Dec 2024 04:28:43 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 4.47%

PREVIOUS CLOSE
CHG
CHG%
$4.20
-0.08
-1.90%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
36%
Profitability 50%
Dept financing 26%
Liquidity 13%
Performance 31%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-10.74%
1 Month
3.85%
3 Months
15.51%
6 Months
13.68%
1 Year
111.76%
2 Year
203.48%
Key data
Stock price
$4.12
P/E Ratio 
-1.87
DAY RANGE
$4.20 - $4.20
EPS 
-$2.93
52 WEEK RANGE
$2.29 - $5.24
52 WEEK CHANGE
$94.59
MARKET CAP 
121.962 M
YIELD 
N/A
SHARES OUTSTANDING 
29.747 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$60,532
AVERAGE 30 VOLUME 
$50,562
Company detail
CEO: Charles R. Mills
Region: US
Website: aziyo.com
Employees: 180
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Aziyo Biologics, Inc. focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device.

Recent news